MRK - Merck & Co., Inc.
| Previous Close | 72.21 |
| Open | 72.30 |
| Bid | 72.05 x 800 |
| Ask | 0.00 x 3000 |
| Day's Range | 71.93 - 72.65 |
| 52 Week Range | 52.83 - 72.89 |
| Volume | 14,513,382 |
| Avg. Volume | 8,452,429 |
| Market Cap | 192.417B |
| Beta (3Y Monthly) | 0.98 |
| PE Ratio (TTM) | 149.18 |
| EPS (TTM) | 0.49 |
| Earnings Date | Oct 25, 2018 |
| Forward Dividend & Yield | 1.92 (2.67%) |
| Ex-Dividend Date | 2018-09-14 |
| 1y Target Est | 76.52 |
- Business Wire•35 minutes ago
First Presentation of Early Data for Merck’s Investigational STING Agonist (MK-1454) in Patients with Advanced Solid Tumors or Lymphomas at ESMO 2018 Congress
New Clinical Findings Involving STING Agonist as Monotherapy and in Combination with an Anti-PD-1 Therapy
- Business Wire•6 hours ago
Merck’s KEYTRUDA® (pembrolizumab) Showed a Complete Response Rate of Nearly 40 Percent in Patients with High-Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Standard of Care
First-Time Data for KEYTRUDA in NMIBC from Phase 2 KEYNOTE-057 Trial to be Presented at ESMO 2018 Congress
- Zacks•16 hours ago
Merck (MRK) Gains As Market Dips: What You Should Know
Merck (MRK) closed the most recent trading day at $72.35, moving +0.19% from the previous trading session.
- Investopedia•19 hours ago
2 Dow Safety Stock for Volatile Market: Portfolio Manager
As the Dow Jones Industrial Average (DJIA) index experiences a period of heightened volatility, healthcare stocks have proved relatively immune to the wider market swings. Healthcare players Pfizer Inc. ( PFE), UnitedHealth Group Inc. ( UNH) and Merck & Co., Inc. ( MRK), all members of the blue chip index, remain within short reach of their 52-week highs, while the DJIA has fallen 5.8% from its own as of Friday afternoon.
- Zacks•23 hours ago
Top Stock Reports for UPS, Merck & BHP Billiton
Top Stock Reports for UPS, Merck & BHP Billiton
- Motley Fool•yesterday
Why Merck's Latest Success Means Trouble for Exelixis Inc.
Selling Cabometyx to an important group of patients is about to get even more difficult.
- ACCESSWIRE•yesterday
Today's Research Reports on Trending Tickers: Merck & Co., and Bristol-Myers Squibb
NEW YORK, NY / ACCESSWIRE / October 19, 2018 / U.S. equities plunged on Thursday as worries over global growth weighed on the broader market and investors continued to digest the minutes from the Federal ...
- The Wall Street Journal•2 days ago
Jim Scholefield Leaves Nike for Top Tech and Digital Job at Merck
Jim Scholefield is leaving as Nike Inc.’s global CIO to join Merck & Co. as chief information and digital officer, effective Oct. 29. Mr. Scholefield will lead Merck’s information technology and digital strategy, the pharmaceutical company said in a statement Wednesday.
- Market Realist•2 days ago
Analyzing Pfizer’s Stock Performance in October
Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17—compared to the previous close.
- Reuters•2 days ago
Merck, Pfizer combo treatment meets main goals of kidney cancer trial
The combination resulted in statistically significant and clinically meaningful improvements in overall survival of the patients and helped patients survive without the cancer worsening, when compared to Pfizer's kidney cancer drug, Sutent. Keytruda is a blockbuster medicine that targets a blockade of proteins known as PD-1 and is approved for a range of other cancers, including lung cancer.
- Reuters•2 days ago
Merck, Pfizer combo treatment meets main goals of kidney cancer trial
Merck & Co said on Thursday a combination treatment of its cancer drug Keytruda and Pfizer Inc's Inlyta met the main goals of a late-stage study in patients with the most common form of kidney cancer. The combination resulted in statistically significant and clinically meaningful improvements in overall survival of the patients and helped patients survive without the cancer worsening, when compared to Pfizer's kidney cancer drug, Sutent.
- Business Wire•2 days ago
Merck’s KEYTRUDA® (pembrolizumab) in Combination with Pfizer’s Inlyta® (axitinib) Significantly Improved Overall Survival (OS) and Progression-free Survival (PFS) as First-Line Therapy for Advanced or Metastatic Renal Cell Carcinoma
KEYTRUDA is First Anti-PD-1 Therapy in Combination to Improve Both OS and PFS in Advanced or Metastatic RCC, the Most Common Type of Kidney Cancer
- Motley Fool•3 days ago
2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.
- American City Business Journals•3 days ago
They tackled chronic cough. Now with $54.5 million, this duo is targeting Alzheimer's and more
After taking a Peninsula startup through a billion-dollar acquisition, Kathy Glaub and Anthony Ford are at it again. The duo are leading CuraSen Theraepeutics Inc., which said Wednesday that it had raised $54.5 million to target Alzheimer's disease, Parkinson's disease and other, less-common neurodegenerative diseases. The Series A round was led by New Leaf Venture Partners and included Longitude Capital, funds managed by Tekla Capital Management LLC, Alta Partners, Pappas Capital and Johnson & Johnson's corporate venture arm.
- Business Wire•3 days ago
Merck Announces Appointment of Jim Scholefield as Chief Information and Digital Officer
Merck (MRK), known as MSD outside the United States and Canada, today announced the appointment of Jim Scholefield as chief information and digital officer, effective Oct. 29, 2018. Scholefield will be responsible for leading Merck’s information technology and digital strategy and will be a member of the company’s Executive Committee.
- Investopedia•3 days ago
5 Blue Chip Drug Stocks Poised for Long-Term Gains
Big pharmaceutical stocks have routinely lagged those of the biotech sector and, so far this year, are underperforming the broader health-care sector by a margin of more than 7%. Citing fading headwinds along with innovation and boosted new-drug sales, Guggenheim’s Seamus Fernandez names Merck & Co. Inc. ( MRK), Allergan PLC ( AGN) and AstraZeneca ( AZN) as three of his favorites, while also giving Eli Lilly & Co. ( LLY) and Novo Nordisk ( NVO) a buy rating, according to Barron’s.
- Yahoo Finance•4 days ago
Big pharma: Trump rule mandating drug prices in TV ads might be unconstitutional
The Trump new administration's proposal to require prescription drug manufacturers to disclose prices in TV ads may be primed for legal challenges.
- Zacks•4 days ago
AstraZeneca's (AZN) Lynparza Gets Another Orphan Drug Status
AstraZeneca (AZN) and partner Merck's Lynparza receive Orphan Drug designation (ODD) by the FDA for the treatment of pancreatic cancer.
Market Realist•4 days agoWhat Nektar Therapeutics’ Valuation Trend Indicates
In October, ten analysts are covering Nektar Therapeutics (NKTR) stock. Eight of them have given the stock a “buy” or higher rating, and two have given it a “hold.” The mean rating for the stock is 1.8 with a target price of $89.38, implying an upside potential of 82.1% over its closing price of $49.08 on October 15.
Market Realist•4 days agoAnalyzing Nektar Therapeutics’ Operational Performance
Nektar Therapeutics’ (NKTR) cost of goods sold was $5.52 million in the second quarter of 2018 compared to $8.99 million in the second quarter of 2017.
- Business Wire•4 days ago
U.S. FDA Grants LYNPARZA® (olaparib) Orphan Drug Designation for Pancreatic Cancer
Fourth Orphan Drug Designation in the U.S. for AstraZeneca and Merck’s LYNPARZA
- The Wall Street Journal•4 days ago
[$$] European Corporate News Roundup
A $900 million disposal by Spain’s Iberdrola and a revenue warning from British American Tobacco are the corporate highlights in Europe on Tuesday.
Market Realist•5 days agoMerck’s Operating Expenditure and Recent Developments
Merck’s (MRK) M&P (materials and production) expenses grew ~10% YoY (year-over-year) to $3.4 billion in the second quarter of 2018, while its M&A (marketing and administrative) expenses were flat YoY at $2.5 billion. The company’s R&D (research and development) expenses grew ~28% YoY to $2.3 billion from $1.8 billion, and its restricting expenditure grew 37% YoY to $228.0 million from $166.0 million. Analysts expect Merck to report non-GAAP M&P expenses of $2.7 billion in the third quarter, and non-GAAP R&D expenses of $2.0 billion.
Market Realist•5 days agoMerck Is Expected to Record Steady Revenue Growth in Q3
Merck has announced it will be presenting its third-quarter revenue and earnings results on October 25. Analysts expect Merck to report revenue of $10.9 billion, primarily supported by Keytruda label expansions, Bridion, and its vaccine portfolio.
- Yahoo Finance Video•4 days ago
Government wants drug companies to disclose prices on TV ads
New regulation could force drug companies to disclose their prices on TV ads. Yahoo Finance's Seana Smith, Zack Guzman and Sibile Marcellus discuss.
